DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Early Phase 1

Completed

Conditions: Metastatic Melanoma
Metastasis to Brain

Interventions: Drug: Nivolumab + Relatlimab
Drug: Nivolumab
Procedure: Standard of Care Craniotomy
Drug: Ipilimumab

First Posted Date: 2023-01-30

Last Posted Date: 2025-03-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 1

Registration Number: NCT05704933

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Phase 1

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma
Triple Negative Breast Cancer Malignancies
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: PRGN-3007

First Posted Date: 2023-01-23

Last Posted Date: 2025-04-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT05694364

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Recruiting

Conditions: Chronic Pancreatitis
FAP
Pancreatic Ductal Adenocarcinoma
Genetic Pancreatitis
Pancreatic Cyst
Fatty Pancreas
Familial Atypical Multiple Mole-Melanoma
Peutz-Jeghers Syndrome
Ataxia Telangiectasia
Genetic Pancreatic Cancer

Interventions: Other: Data collection

First Posted Date: 2023-01-20

Last Posted Date: 2025-03-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 500

Registration Number: NCT05692596

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

Recruiting

Conditions: Pancreatic Cancer

Interventions: Other: Blood Sample Collection
Other: Tissue Sample Collection
Other: Data Collection
Other: Medical Image Collection

First Posted Date: 2023-01-18

Last Posted Date: 2025-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 125

Registration Number: NCT05687188

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Phase 1

Recruiting

Conditions: Non Small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Recurrent Non Small Cell Lung Cancer

Interventions: Biological: Tumor-infiltrating Lymphocytes (TIL)
Drug: Nivolumab
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Tumor-infiltrating Lymphocyte Therapy
Drug: Interleukin-2 (IL2)

First Posted Date: 2023-01-12

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT05681780

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

Not Applicable

Recruiting

Conditions: Human Papilloma Virus (HPV) Vaccine

Interventions: Behavioral: HPV MISTICS -Provider Level
Behavioral: HPV MISTICS - Parent Level
Behavioral: HPV MISTICS- HPV Vaccine Champion Level

First Posted Date: 2023-01-10

Last Posted Date: 2025-05-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 564

Registration Number: NCT05677360

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

Not Applicable

Recruiting

Conditions: Pancreatic Cancer

Interventions: Behavioral: Consultations with Moffitt Dietician
Behavioral: Daily Food Intake Diary with Fitbit Smartphone application
Behavioral: Questionnaires

First Posted Date: 2023-01-09

Last Posted Date: 2025-04-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 80

Registration Number: NCT05675059

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

Recruiting

Conditions: Adenocarcinoma of Lung
Lung; Node

Interventions: Diagnostic Test: DetermaRX

First Posted Date: 2022-12-27

Last Posted Date: 2025-03-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 250

Registration Number: NCT05665504

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

Phase 1

Recruiting

Conditions: Gastrointestinal Cancer

Interventions: Behavioral: Tele-Resistance Training

First Posted Date: 2022-12-23

Last Posted Date: 2025-03-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 100

Registration Number: NCT05664178

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Early Phase 1

Recruiting

Conditions: Advanced Basal Cell Carcinoma

Interventions: Drug: Vismodegib 150 MG Oral Capsule

First Posted Date: 2022-12-15

Last Posted Date: 2025-03-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 34

Registration Number: NCT05651828

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy